Maravai LifeSciences Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
Maravai LifeSciences (MRVI) reported third-quarter revenue of $45.9 million, marking a 10% year-over-year increase. The growth was primarily driven by the TriLink segment, which saw a 12% rise fueled by strong demand for mRNA products and discovery mRNA services. Notably, the company's adjusted gross margin expanded significantly by 1,700 basis points to 57.7%, reflecting improved operational efficiency and a favorable product mix. Despite reporting a GAAP net loss of $24 million, the company showed marked improvement from the previous year's loss of $45.1 million. Driven by strong performance in mRNA consumables and biologics safety testing, management raised its full-year revenue guidance to a range of $212 million to $216 million and increased its adjusted EBITDA outlook to $40 million–$42 million.
Tickers: $MRVI
Topics: EBITDA gross margin expansion mRNA products revenue growth